Chapters

Transcript

Video

What do you hope to learn from ARTISTRY-7 as it relates to the efficacy and safety of nemvaleukin as monotherapy or as part of combinatorial therapy with immune checkpoint inhibitors and, even, chemotoxic agents in the setting of solid tumors?


Created by

CMEducation Resources | iQ&A Cytokine Immunotherapy Intelligence Zone

Presenter

John L. Hays, MD

John L. Hays, MD

Associate Professor, Department of Internal Medicine
Medical Director of the Clinical Trials Office
The Ohio State University College of Medicine
Wexner Medical Center & James Cancer Hospital
Columbus, OH